4-fluoro benzoyl-TN-14003(BKT140, motixafortide) is a high-affinity CXCR4 antagonist, which can inhibit the migration of prostate cancer cells (Peng and Kopecek, 2014). This evidence concerns the gene CXCR4 and prostate carcinoma.